Literature DB >> 14608527

Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients.

Dilek Yavuz1, Mehmet Koç, Ahmet Toprak, Ihsan Akpinar, Ayliz Velioğlu, Oguzhan Deyneli, Goncagül Haklar, Sema Akalin.   

Abstract

OBJECTIVE: Disturbed endothelial function is closely associated with hyperinsulinaemia and insulin resistance in essential hypertension. The aims of this study were: 1) to evaluate whether the two alternative drugs, angiotensin-converting enzyme (ACE) inhibitors and Angiotensin II (Ang II) antagonists, had comparable effects on glucose metabolism and endothelial function. 2) to determine whether they improve endothelial dysfunction through modulating insulin resistance and oxidative stress. STUDY DESIGN AND METHODS: Essential hypertensive patients were randomised into two groups: Twelve (nine patients in final analysis) patients were given enalapril (enalapril group), and twelve (nine patients in final analysis) were given losartan (losartan group). Twelve sex- and age-matched normotensive volunteers were included as controls. Before and after six months of treatment, endothelial function, insulin sensitivity and lipid peroxidation (TBARs) and NO metabolites (NOx) were evaluated.
RESULTS: Endothelial function, measured as flow mediated dilatation (FMD), was improved in both of the treatment groups (p=0.0001). Calculated insulin sensitivity index also improved in the enalapril-treated group (p=0.05) but not in the losartan-treated group, compared with baseline levels. TBARS values decreased significantly in the enalapril group compared with baseline levels (p<0.001). FMD was positively correlated with insulin sensitivity index (r=0.32, p<0.05) and NOx levels (r=0.39, p=0.01) and negatively correlated with TBARS levels (r=-0.53, p=0.0002) in hypertensive patients.
CONCLUSION: Inhibition of the renin-angiotensin system, either with ACE inhibitors or AT(1)-receptor blockers improves endothelial dysfunction. ACE inhibition has prominent effects on improving insulin sensitivity and decreasing oxidative stress in essential hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14608527     DOI: 10.3317/jraas.2003.032

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  19 in total

Review 1.  Endothelial dysfunction in obstructive sleep apnea.

Authors:  Rohit Budhiraja; Sairam Parthasarathy; Stuart F Quan
Journal:  J Clin Sleep Med       Date:  2007-06-15       Impact factor: 4.062

Review 2.  Ace inhibitors as a therapy for sarcopenia - evidence and possible mechanisms.

Authors:  D Sumukadas; M D Witham; A D Struthers; M E T McMurdo
Journal:  J Nutr Health Aging       Date:  2008 Aug-Sep       Impact factor: 4.075

3.  Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension.

Authors:  A A Lteif; R L Chisholm; K Gilbert; R V Considine; K J Mather
Journal:  Diabetes Obes Metab       Date:  2011-11-24       Impact factor: 6.577

4.  Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers.

Authors:  Pamela S Silva; Vanessa Fontana; Ana C T Palei; Jonas T C Sertório; Celso Biagi; Jose Eduardo Tanus-Santos
Journal:  Eur J Clin Pharmacol       Date:  2011-02-09       Impact factor: 2.953

Review 5.  Role of heme oxygenase in inflammation, insulin-signalling, diabetes and obesity.

Authors:  Joseph Fomusi Ndisang
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

6.  Mesenteric artery remodeling and effects of imidapril and irbesartan on it in spontaneously hypertensive rats.

Authors:  Zhong-Sheng Zhu; Jin-Ming Wang; Shao-Liang Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

7.  Prevention of DNA damage in renal transplantation by losartan and enalapril: the role of renin-angiotensin system polymorphisms.

Authors:  Amir Ghorbanihaghjo; Pegah Veisi; Hassan Argani; Mohammad Aghaeishahsavari; Masood Noroozianavval; Nadereh Rashtchizadeh; Mehran Mesgari; Javid Safa; Hosain Babaei
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

Review 8.  The vascular endothelium in diabetes--a therapeutic target?

Authors:  Kieren J Mather
Journal:  Rev Endocr Metab Disord       Date:  2013-03       Impact factor: 6.514

Review 9.  Prehypertension: risk stratification and management considerations.

Authors:  Brent M Egan; Stevo Julius
Journal:  Curr Hypertens Rep       Date:  2008-10       Impact factor: 5.369

Review 10.  Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention.

Authors:  Maria M Patarroyo Aponte; Gary S Francis
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.